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SUMMARY
We aimed to evaluate patient factors including nonadherence and viral
infection and de novo donor-specific antibody (dnDSA) characteristics [to-
tal immunoglobulin G (IgG), C1q, IgG3, and IgG4] as predictors of renal
allograft failure in a multicenter cohort with dnDSA. We performed a ret-
rospective observational study of 113 kidney transplant recipients with
dnDSA and stored sera for analysis. Predictors of death-censored allograft
loss were assessed by Cox proportional modeling. Death-censored allograft
survival was 77.0% (87/113) during a median follow-up of 2.2 (IQR 1.2–
3.7) years after dnDSA detection. Predictors of allograft failure included
medication nonadherence [HR 6.5 (95% CI 2.6–15.9)], prior viral infection
requiring immunosuppression reduction [HR 5.3 (95% CI 2.1–13.5)],
IgG3 positivity [HR 3.8 (95% CI 1.5, 9.3)], and time post-transplant
(years) until donor-specific antibody (DSA) detection [HR 1.2 (95% CI
1.0, 1.3)]. In the 67 patients who were biopsied at dnDSA detection,
chronic antibody-mediated rejection [HR 11.4 (95% CI 2.3, 56.0)] and
mixed rejection [HR 7.4 (95% CI 2.2, 24.8)] were associated with allograft
failure. We conclude that patient factors, including a history of viral infec-
tion requiring immunosuppression reduction or medication nonadherence,
combined with DSA and histologic parameters must be considered to
understand the risk of allograft failure in patients with dnDSA.
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Introduction
De novo donor-specific antibody (dnDSA) is a major
risk factor for chronic active antibody-mediated rejec-
tion (ABMR) and subsequent renal allograft loss [1–3],
yet many patients with dnDSA have stable allograft
function for years [4–7]. A clear understanding of the
patient characteristics and biomarkers at the time of
dnDSA detection predictive of allograft loss is needed to
inform management decisions. More importantly, this
information can be used to effectively design clinical tri-
als and define inclusion criteria to enrich study popula-
tions with subjects most likely to reach meaningful
clinical end points.
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Previous studies have shown that allograft dysfunc-
tion and histologic features of rejection help predict
allograft loss [4,6], but this information is not always
apparent at the time of initial dnDSA detection. The
patients who develop dnDSA are also heterogeneous.
The main precursors to dnDSA include patient medica-
tion nonadherence and provider initiated immunosup-
pression reduction (i.e., for infection) [1,4,5,8], but it
remains unclear whether these factors are important in
predicting early allograft loss.
One important biomarker of allograft loss is DSA.
The routine single antigen bead (SAB) assay for anti-
HLA antibody detection provides valuable semi-quanti-
tative information about immunoglobulin G (IgG)
directed toward class I and/or class II HLA. However,
other dnDSA information may also have prognostic
value such as the specific IgG subclass profile or com-
plement binding ability of the dnDSA. The different
IgG subclasses have distinct effector functions, notably a
differential ability to bind complement and the Fc
receptor. These factors likely influence allograft histol-
ogy and allograft loss [9–11]. Previous studies have sug-
gested that IgG3-positive DSA, C1q binding positivity,
quantity of DSA as measured by mean fluorescence
intensity (MFI) or titer, and the HLA class of DSA are
predictive of allograft failure [4,12–20] in single center
cohorts; but these factors have not been systematically
studied in a diverse multicenter cohort in the context of
other important predictors of allograft failure.
The objective of our project was twofold. First, we
aimed to determine the death-censored allograft survival
and allograft histology following the identification of
dnDSA in a well-characterized multicenter cohort of
kidney transplant recipients. Second, we aimed to iden-
tify unique patient, histological, and dnDSA characteris-
tics associated with early allograft failure. Patient factors
studied included baseline demographics, nonadherence,
or prior viral infection requiring immunosuppression
reduction. dnDSA characteristics included IgG sub-
classes and C1q binding positivity.
Methods
Study design
This was a retrospective observational multicenter study
of solitary kidney transplant recipients transplanted
from 1998 to 2015 [Mayo Clinic, Rochester, MN, USA
(Center A); New York Presbyterian Weill Cornell Medi-
cal College [NYP-WCM (Center B)], New York, NY,
USA; and University of Michigan, Ann Arbor, MI, USA
(Center C)] with dnDSA. A chart review was performed
to identify patients meeting the following inclusion cri-
teria: (i) no DSA at the time of transplant; (ii) develop-
ment of dnDSA with MFI >1000 post-transplantation
verified on two independent tests; and (iii) the availabil-
ity of banked sera collected at the time of dnDSA detec-
tion to allow for additional DSA characterization at a
central laboratory (Terasaki Research Institute, Los
Angeles, CA, USA). The overall aim of the study was to
determine the factors identified at initial dnDSA detec-
tion that were associated with allograft loss. This study
was approved by the Institutional Review Boards at
Mayo Clinic, NYP-WCM, and University of Michigan.
Clinical data were collected by chart review.
De novo donor-specific antibody assessment
Donor-specific antibody testing was performed using the
SAB solid phase assay (LABscreen; One Lambda, Canoga
Park, CA, USA). An MFI cutoff of 1000 was considered
positive. All patients were negative for DSA pretransplant
and had at least one SAB test negative for DSA post-
transplant. DSA testing and screening were performed for
surveillance purposes at least yearly post-transplant and
as indicated at the time of allograft dysfunction.
The stored sera obtained when dnDSA was initially
detected was sent to the Terasaki Research Institute for
repeat testing using a standard protocol to confirm the
presence of dnDSA and perform IgG subclass and C1q
testing. Pan IgG DSA testing was also done via the SAB
assay. The dnDSA with the highest MFI at presentation
was considered the Dominant DSA.
The methodology of IgG subclass typing with Lumi-
nex has been previously described in detail [12]. Briefly,
the LABScreen assay was performed according to the
manufacturer’s instructions, except for the replacement
of phycoerythrin (PE)-conjugated secondary mouse
monoclonal anti-human IgG (One Lambda Inc.) with
different PE-mouse anti-human IgG specific to IgG sub-
class hinge regions (IgG3: HP6050; Southern Biotech
Inc., Birmingham, AL, USA), and the Fc prime portion
of the heavy chain (IgG4: HP6023; Southern Biotech
Inc.). The trimmed MFI values were normalized using
the formula: ([sample #N beads-sample negative control
beads]  [negative control #N beads-negative control
beads]).
For the C1q assay, the test was performed using heat-
inactivated serum (56 °C for 30 min) that was spiked
with 150 mg/ml purified human C1q in HEPES buffer
(One Lambda) to ensure equal functional amounts of
C1q per sample. LABScreen single antigen beads were
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added to the mixture and incubated for 20 min at room
temperature, followed by addition of phycoerythrin
conjugated anti-human C1q. Beads were washed twice
and analyzed on a LABScan200 flow analyzer (i.e.,
Luminex). A cutoff of 1000 MFI was used to indicate
positivity for all IgG and C1q testing unless otherwise
indicated.
Assessment of medication adherence
We defined medical nonadherence as documented miss-
ing labs, unexplained low immunosuppressive drug levels,
no-show to appointments, medications not refilled, docu-
mentation of nonadherence by treating physician in the
medical record, or by the patient’s own admission. These
events occurred prior to appearance of dnDSA, and were
therefore considered a baseline variable.
Assessment of viral infection
Patients were monitored for viral infections based on
center practices and clinical indications. The presence of
a prior viral infection requiring immunosuppressive
reduction was defined by both a positive blood PCR
assay and physician initiated immunosuppressive reduc-
tion. The specific viruses considered for this study
included BK viremia and/or nephropathy, Epstein–Barr
virus (EBV), cytomegalovirus (CMV), and parvovirus.
BK viremia and/or nephropathy was also considered as
a separate variable.
Biopsy assessment
We analyzed the allograft biopsy findings from a subset
of patients (N = 67) who received a biopsy at the time
of dnDSA detection. Biopsies were performed according
to the individual transplant center’s surveillance proto-
col and provider discretion (i.e., dnDSA). Kidney biopsy
tissue was processed for light microscopy and C4d if
indicated. At Centers A and B, C4d was detected by
immunofluorescence (AbD Serotec). At Center C, C4d
was detected by immunohistochemistry. Biopsies were
scored using the Banff 2017 classification system [21–
23]. Borderline acute cellular rejection was considered
an acute cellular rejection (ACR) for our purposes.
Specifically, active antibody-mediated rejection (ABMR)
was diagnosed if two features were present according to
Banff 2017 classification system [24]: (i) Histologic evi-
dence of acute tissue injury including g > 0 and/or
ptc > 0, intimal or transmural arteritis (v > 0), throm-
botic microangiopathy, or acute tubular injury, in the
absence of any other apparent cause; and (ii) Evidence
of current/recent antibody interaction with vascular
endothelium including at least one of the following:
C4d ≥2 with immunofluorescence, C4d ≥1 with
immunohistochemistry on frozen section, or
g + ptc ≥ 2. The presence of cg score >0 signified in
addition to active ABMR features signified chronic
ABMR. Electron microscopy was not routinely done in
all biopsies, and it was not used to determine the pres-
ence of chronic ABMR.
Patient treatment
Treatment for dnDSA and/or ABMR was based on the
individual centers protocol and biopsy results. At Center
A, only patients with ABMR and T-cell-mediated rejec-
tion received treatment with plasmapheresis, intra-
venous immunoglobulin (IVIG), and anti-thymocyte
globulin. At Center B, patients received treatment based
on biopsy findings and allograft function. Patients with
dnDSA and ABMR with stable allograft function
received steroid pulse with IVIG. Patients with dnDSA
and ABMR who had allograft dysfunction received ster-
oid pulse, plasmapheresis, IVIG, and bortezomib.
Patients with dnDSA and ABMR with T-cell-mediated
rejection received steroid pulse and anti-thymocyte
globulin. At Center C, all patients with active ABMR
received plasmapheresis and IVIG. If a combined T-cell-
mediated rejection was identified, the patient also
received intravenous steroids and anti-thymocyte globu-
lin. For chronic active ABMR, patients received intra-
venous immunoglobulin for 4 weeks. At all centers, no
treatment was given to patients with dnDSA and no
histologic evidence rejection (patients who did not
receive a biopsy or patients who received a biopsy that
was negative for ABMR).
Laboratory monitoring
All patients had serum creatinine levels and estimated
glomerular filtration rate (GFR) reported at least every
3 months per center protocol.
Statistical analysis
Statistical analysis was performed on JMP v10. (SAS,
Cary, NC, USA) and R v3.4.1 (Austria). For numerical
data, groups were compared with the t-test or the Wil-
coxon rank sum test as indicated. Counts and percent-
ages were compared using the chi-squared test. Matched
pairs analysis was done to compare allograft function
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among individuals prospectively. Time-to-event data
were summarized for each group using Kaplan–Meier
estimates. Univariate and multivariate analysis for corre-
lates with post-dnDSA allograft loss was done using
Cox proportional hazards models using the date of
dnDSA diagnosis as the index date. Variables were
included in the multivariate analysis if the univariate P-
value was less than 0.15 and variable selection was per-
formed with backwards stepwise variable selection using
the Schwarz’s Bayesian criterion. Hazards ratios (HR)
were described by their point estimate and correspond-
ing 95% confidence intervals (CI). Statistical signifi-
cance was defined by P < 0.05 for two-sided P-values.
Assumptions of proportionality were tested through
the Schoenfeld residuals using the cox.zph() routine in R.
Nonlinearity of variables entering models were tested
using polynomial splines. An interaction term between
C1q and IgG3 was included in the multivariable model in
order to test for synergy between the two DSA subtypes.
Results
Patient characteristics
A total of 113 patients with dnDSA and banked serum
collected at the time of initial DSA detection were
included in the study (n = 28 from Center A, n = 35
from Center B, and n = 50 from Center C) Table 2.
The mean age  SE was 41.4  1.5 years old, the
majority of subjects were male [66.4% (75/113)], and
the main cause of end stage renal disease was glomeru-
lonephritis [35.4% (40/113)]. The racial composition of
the cohort was diverse and varied among centers
(P = 0.02). Notably, 25.7% (29/113) of patients were
African American and 12.4% (14/113) were Hispanic.
The donor type and the proportion with prior trans-
plant also varied by center (P < 0.01 and P = 0.02,
respectively), and included 44.3% (50/113) deceased
donor recipients and 16.8% (19/113) with prior failed
kidney transplant. The proportion of patients with 0–2
HLA mismatches was 7.1% (8/113), 3–4 HLA mis-
matches was 39.8% (45/113), and 5–6 mismatches was
53.1% (27/113). The prevalence of documented medica-
tion nonadherence was 31.0% (35/113) overall and was
similar among the participating centers, P = 0.07. A
viral infection requiring reduction in immunosuppres-
sion prior to the detection of DSA was present in
30.1% (34/113) of patients. Of note, 4.4% (5/113)
patients had a documented history of medication non-
adherence and also experienced a viral infection prior
to the detection of dnDSA.
Induction immunosuppression varied among centers
(P < 0.0001), but 73.5% (83/113) received anti-thymo-
cyte globulin. The majority of recipients were treated
with a combination maintenance immunosuppressive
regimen including tacrolimus [80.5% (91/113)],
mycophenolate mofetil [94.7% (107/113)], and steroids
[69.0% (78/113)]. A larger proportion of patients
received maintenance immunosuppression with cyclos-
porine at Center C than other centers, and fewer
patients were on a long-term steroids at Center B
(P < 0.01). Other patient characteristics are included in
Table 1.
DSA characteristics at the time of de novo DSA
detection
The median (IQR) time post-transplant until the detec-
tion of dnDSA was 1.1 (0.6–2.8) years, and this was dif-
ferent among centers, P < 0.01. At Center A, the
median (IQR) time to detection was 1.0 (0.8–3.8) years,
at Center B it was 0.9 (0.6–1.3) years, and at Center C
it was 2.1 (0.5–5.1) years post-transplant. Using the
conventional LABScreen pan IgG assay, 18.5% (21/113)
of the patients had dnDSA against class I only, 54.0%
(61/113) had dnDSA against anti-class II only, and
27.4% (31/113) had dnDSA against both class I and
class II Tables 2 and S1. The median (IQR) MFI of the
dominant DSA was 9592 (IQR 3362–14 923) and was
similar among centers (P = 0.05).
Immunoglobulin G3 (MFI ≥1000) at dnDSA onset was
found in 25.7% (29/113) of patients and this was different
among centers, P = 0.02 [Center A = 42.9% (12/28),
Center B = 11.4% (4/35), and Center C = 26.0% (13/50);
Table 2]. IgG4 positivity (MFI ≥1000) was found in only
15.0% (17/112) of patients and C1q binding was found in
10.6% (12/113). The prevalence of IgG4 and C1q binding
was statistically similar among centers, P = 0.35, and
P = 0.06, respectively (Table 2). The presence of IgG3,
IgG4, and C1q positivity at dnDSA initial detection was
positively correlated with the MFI of the dominant DSA
as shown in Fig. 1.
The combinations of C1q and IgG subclass positivity
and associated patient and pan IgG characteristics are
detailed in Fig. S1. The majority of patients [66.4% (75/
113)] were negative for IgG3, IgG4, and C1q, while only
3.5% (4/113) were positive for all three of these charac-
teristics (C1q, IgG3, and IgG4). C1q and IgG3 (IgG4)
was positive in 8.0% (9/113). Of the C1q-positive
patients, 75.0% (9/12) were also positive for IgG3. Con-
versely, of the IgG3-positive patients, 40.9% (9/22) were
positive for C1q.
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Allograft survival and function
The incidence of death-censored allograft failure by
1 year post-dnDSA was 8.0% (9/113); and by 3 years
post-dnDSA 32.2% (20/62) of the patients experienced
allograft failure. Overall allograft survival was 75.2%
(85/113) and death-censored allograft survival was
77.0% (87/113) during a median follow-up of 2.2
(IQR 1.2–3.7) years post-dnDSA detection Fig. 2. Both
were similar among centers (P = 0.57 and P = 0.52,
respectively).
The median estimated GFR (IQR) at the time of
dnDSA detection was 52.4 ml/min/1.73 m2 (IQR
37.8–67.2) mg/dl and was similar at 52.2 ml/min/
1.73 m2 (IQR 33.85–70.3) within 6–12 month post-
dnDSA detection (P = 0.88). Within 24 months of
dnDSA detection, the median estimated GFR
decreased to 46.5 ml/min/1.73 m2 (P = 0.02).
Factors associated with allograft failure
Factors associated with death-censored allograft failure
by univariate Cox proportional hazard analysis and
subsequently included in the multivariable analysis
(P ≤ 0.15) included history of nonadherence, viral
infection requiring immunosuppression reduction
prior to dnDSA detection, C1q (MFI >1000), IgG3
(MFI >1000), and the time to dnDSA post-transplant
in years Table 3. Factors not associated with death-
censored allograft failure included the age of the recip-
ient, race, deceased donor, steroid containing
immunosuppression, history of prior kidney trans-
plant, BK nephropathy prior to dnDSA, dominant
DSA MFI, number of DSA specificities, class of DSA,
and transplant center.
In a multivariate model using stepwise variable
selection, predictors of allograft failure included his-
tory of medication nonadherence [HR 6.5 (95% CI
2.6–15.9)], viral infection prior to DSA detection [HR
5.3 (95% CI 2.1–13.5)], IgG3 positivity [HR 3.8 (95%
CI 1.5–9.3)], and the time post-transplant until detec-
tion of dnDSA [1.2 (1.0, 1.3) in years Table 3]. The
C-statistic was 0.80 for this model.
Allograft survival in the context of medication
nonadherence and/or viral infection
Given that both medication nonadherence and prior
history of viral infection were associated with allograft
failure, we examined allograft survival in the following
subgroups: (i) those with documented history ofT
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medication nonadherence (n = 30), (ii) those with his-
tory of viral infection leading to immunosuppression
reduction [n = 34, five of which also had documented
nonadherence], and (iii) those with neither nonadher-
ence or prior viral infection. Death-censored allograft
survival following dnDSA was 70.0% (21/30) in the
medication nonadherence group, 67.4% (23/34) in the
prior viral infection group, and 87.8% (43/49) in the
group with neither medication nonadherence nor prior
viral infection during a mean follow-up of 2.2 (IQR
1.2–3.7) years post-dnDSA detection, P = 0.009, Fig. 3.
There was numerical trend toward an increased fre-
quency of IgG3+ DSA in the dnDSA-nonadherence
group [33.3% (10/30) in the nonadherence group vs.
17.7%(6/24) in dnDSA-viral infection group and 22.5%
(11/49) in the neither group], but this did not reach
statistical significance. The number of DSA, class of
DSA, frequency of C1q+ DSA, and frequency of IgG4
DSA was similar among the three groups.
Allograft histology at the time of de novo DSA
detection
Sixty-seven (59.3%) patients received a kidney biopsy at
the time of dnDSA detection. The majority [71.6% (48/
67)] showed evidence of ABMR. Of those cases, 33.3%
(16/48) demonstrated chronic active ABMR. The speci-
fic biopsy findings stratified by center are shown in
Fig. 4. A mixed ABMR and T-cell-mediated rejection
was present on 32.8% (22/67), while an isolated ABMR
(active or chronic) was present on 38.8% (26/67) of
biopsies. An isolated T-cell-mediated rejection was
found in only 6.0% (4/67) of biopsies and 22.4% (15/
67) of biopsies were negative for rejection.
The presence of chronic ABMR [HR 11.4 (95% CI
2.3–56.0)] or a mixed rejection [HR 7.4 (95% CI 2.2,
24.8)] were associated with allograft failure. When
chronic ABMR was present; 43.8% (7/16) of patients
had allograft loss. When mixed rejection was present,
27.3% (6/22) had allograft loss. Isolated acute active
ABMR, isolated ACR, or no rejection were not associ-
ated with early allograft loss after a mean follow-up of
2.2 (IQR 1.2–3.7) years.
Patients with chronic ABMR at the time of dnDSA
detection were more likely to be nonadherent [56.3% (9/
16) vs. 25.5% (13/51), P < 0.02] than patients with other
biopsy findings. Additionally, patients with chronic
ABMR presented with dnDSA later post-transplant than
those without chronic ABMR (a mean  SD of
7.1  4.0 vs. 4.2  2.2 SD years post-transplant, respec-
tively, P = 0.01). Recipient age, history of BK infection,
previous transplantation, and gender were similar among
individuals with and without chronic ABMR.
Patients with dnDSA positive for IgG3 were more likely
to have a mixed rejection, but we did not detect a relation-
ship among C1q binding, IgG3, or IgG4 subclasses and
the histologic findings of no rejection, acute cellular rejec-
tion only, ABMR only, or chronic ABMR Table S2.
Given the relationship between IgG3 and graft loss,
we compared allograft survival among biopsied patients
who were negative for chronic ABMR and IgG3,
patients who were IgG3 positive but were negative for
chronic ABMR, and those who had chronic ABMR
(IgG3 positive or negative). Allograft survival was
decreased in patients with chronic ABMR (P = 0.0001),
but allograft was similar among patients who did not
have chronic ABMR regardless of IgG3 status (P = 0.17;
Fig. 5).
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Importantly, the biopsy findings at the time of
dnDSA detection were similar among centers (P = 0.76)
and no difference in death-censored allograft loss was
observed among those patients with or without biopsies
performed at this time point [17.9% (12/67) allograft
loss in patients with a biopsy vs. 30.4% (14/46) allograft
loss in patients without a biopsy, P = 0.12].
Discussion
In our analysis of a large and diverse multicenter cohort
with dnDSA; we confirmed that a history of nonadherence
and IgG3 positivity are independently associated with
death-censored allograft loss [1,2,4,6,25,26]. In addition,
we show that having a viral infection leading to immuno-
suppression reduction is an indicator of a poor prognosis,
and that patients who develop dnDSA without a clear pre-
cipitant have the best prognosis. Lastly, we have added to
the understanding of the histologic findings at the time of
dnDSA and their prognostic value. The presence of
chronic active ABMR or a mixed ABMR and T-cell-
mediated rejection are both associated with early allograft
loss.
The association between prior viral infection and
allograft loss in patients with dnDSA has not been pre-
viously well-described. Only recently has the link
between BK nephropathy, DSA, and subsequent ABMR
been well-recognized [8,27–30]; but the association
between other viral infections (other than BK) and DSA
has not been shown. Our findings are especially impor-
tant because they suggest that dnDSA that develops fol-
lowing immunosuppression reduction for infection has
a particularly poor prognosis. Our understanding of the
complex interplay of infection, immunosuppression
reduction, DSA, and ABMR remains limited because of
the small number of cases in our cohort, and further
study is needed. Nonetheless, our findings highlight the
need for personalized immunosuppression reduction in
the setting of infection and careful monitoring for
dnDSA.
Our work is also distinctive because we studied many
DSA characteristics simultaneously in a large diverse
cohort tested at a centralized laboratory. We have con-
firmed that IgG3 positivity at the time of dnDSA detec-
tion is strongly associated with early allograft loss in
patients with dnDSA [31,32], but it is important to
acknowledge that many IgG3 negative patients also had
early allograft loss. IgG3 positivity at the time of dnDSA
was present in only 43.2% (11/26) of the allograft loss
cases. Other studies have indicated that patients develop
IgG3 over time, thus it is possible that IgG3 DSA was
present prior to dnDSA detection with screening or
developed later.
We also found that when considering multiple fac-
tors, C1q positivity did not enter the final prediction
model for early allograft loss in patients with dnDSA.
This finding is likely because of the overlap between
IgG3 and C1q positivity. Our results are consistent with
other studies that have been mixed regarding the role of
C1q positivity for risk stratification in patients with
dnDSA [14,25,33–35].
We acknowledge that evaluating DSA characteristics
is complex. Alloantibody production is a dynamic pro-
cess that can evolve. Additionally, IgG3, IgG4, C1q posi-
tivity, and the presence of class I and class II DSA were
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Figure 2 Overall and death-censored allograft survival after dnDSA
detection was similar among centers. The incidence of death-cen-
sored allograft failure by 1 year post-dnDSA was 8.0% (9/113); and
by 3 year post-dnDSA 32.2% (20/62) of the patients lost their graft.
Overall allograft survival was 75.2% (85/113) (a) and death-censored
allograft survival was 77.0% (87/113) (b) during a median follow-up
of 2.2 (IQR 1.2–3.7) years following dnDSA detection. dnDSA, de
novo donor-specific antibody.
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Table 3. Univariate and multivariate predictors of allograft loss.
Variable
Univariate Stepwise model
HR P HR P
Age of recipient 1.0 (1.0, 1.0) 0.45
Race 0.9 (0.4, 2.0) 0.86
Deceased donor 0.9 (0.4, 1.9) 0.79
Steroid containing immunosuppression 1.8 (0.7, 4.9) 0.22
History of nonadherence 3.2 (1.5, 7.0) 0.002 6.5 (2.6, 15.9) <0.0001
Prior kidney transplant 0.8 (0.3, 2.1) 0.60
Viral infection requiring immunosuppression reduction 2.1 (0.9, 4.6) 0.07 5.3 (2.1, 13.5) 0.0004
BK nephropathy prior to DSA 1.2 (0.4, 4.1) 0.75
C1q (MFI >1000) 5.9 (2.3, 15.6) 0
IgG3 (MFI >1000) 3.2 (1.5, 7.0) 0.002 3.8 (1.5, 9.3) 0.0039
IgG4 (MFI >1000) 2.1 (0.8, 5.7) 0.14
Dominant MFI (Log) 1.4 (0.46, 4) 0.57
Number of DSA specificities 1.1 (0.9, 1.3) 0.35
Anti-class I DSA only 0.7 (0.2, 2.1) 0.52
Anti-class II DSA only 0.7 (0.3, 1.5) 0.36
Both anti-class I and II DSA 2.0 (0.9, 4.3) 0.10
Center
Center B –
Center A 1.1 (0.4, 2.8) 0.86
Center C 0.6 (0.2, 1.4) 0.22
Time to dnDSA (years post-transplant) 1.2 (1.1, 1.3) 0.004 1.2 (1.0, 1.3) 0.01
C-stat NA NA 0.80
The interaction term between C1q and IgG subclasses was nonsignificant P > 0.05.
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Figure 3 Death-censored allograft survival was decreased if there was prior history patient induced medication nonadherence or viral infection
leading to immunosuppressive reduction. Death-censored allograft survival following dnDSA was 70.0% (21/30) in the medication nonadher-
ence group, 67.4% (23/34) in the prior viral infection group, and higher at 87.8% (43/49) in the group with neither medication nonadherence
nor prior viral infection during a mean follow-up of 2.2 (IQR 1.2–3.7) years post-dnDSA detection, P = 0.009. dnDSA, de novo donor-specific
antibody.
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all correlated with pan IgG DSA MFI. However, the
challenge of using MFI alone is that this result is semi-
quantitative and issues such as prozone and assay inter-
ference need to be considered [18]. Obtaining DSA titer
can be done to better quantify DSA, but this is imprac-
tical because it is labor intensive and expensive.
We have previously shown that histologic findings of
ABMR (acute or chronic) were associated with allograft
loss [4], but it appears that the main factor leading to
early allograft loss is chronic ABMR. Mixed ABMR is
also associated with allograft loss, but to a lesser extent.
These findings are supported by others [4,6]. Although
it is logical that patients with chronic ABMR will have
earlier allograft loss, our findings are critical to consider
when designing clinical trials. Patients with dnDSA who
have isolated active ABMR on their initial biopsy are
less likely to reach key end points such as allograft loss
in the short term. Likewise, patients with chronic
ABMR should be cautiously selected in therapeutic clin-
ical trials given the potential lack of response.
We acknowledge the significant heterogeneity in the
centers who contributed patients for this study (varied
baseline immunosuppression, follow-up, and treat-
ment). However, “center” was not a univariate or mul-
tivariate predictor of allograft loss and death-censored
allograft survival and allograft histology at the time of
dnDSA detection was similar among centers. It is possi-
ble that we were underpowered to detect center differ-
ences, but the allograft survival following dnDSA in our
cohort was consistent with what has been previously
published [13,17,25]. Future multicenter prospective
studies in which patients receive standardized treatment
and long-term follow-up are needed to overcome the
limitations of our retrospective study design. A stan-
dardized treatment approach and long-term follow-up
would also allow us to examine the effect of treatment
on DSA characteristics and the evolution of DSA char-
acteristics and histology. A prospective study would also
allow us to determine the incidence of dnDSA, which
was not the purpose of the present study. Further study
All
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P = value
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Figure 4 Allograft histology at the time of de novo DSA detection. Importantly, the biopsy findings at the time of de novo DSA detection
were similar among centers (P = 0.76) and no difference in death-censored graft loss was observed among those patients with or without
biopsies performed at this time point [17.9% (12/67) allograft loss in patients with a biopsy vs. 30.4% (14/46) allograft loss in patients without
a biopsy, P = 0.12]. DSA, donor-specific antibody.
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is also needed to better understand the relationship
between infection, dnDSA, and allograft loss.
In conclusion, a combination of patient historical fac-
tors, DSA characteristics, and histologic findings need
to be considered to determine the risk of allograft fail-
ure in a patient with newly detected DSA after kidney
transplant. DSA characteristics such as IgG3 positivity
are predictive of early graft loss, but other factors are
also important. A prior history of viral infection leading
to immunosuppressive reduction, nonadherence, and
allograft histology must all be considered when design-
ing therapeutic clinical trials to appropriately include
patients most likely to reach meaningful clinical end
points such as allograft loss. Understanding of the risk
factors associated with allograft loss can inform patient
management decisions in clinical practice and improve
outcomes.
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